Dr. Tripathy on the Oncotype DX Assay Recurrence Score

Debu Tripathy, MD
Published: Monday, Aug 15, 2011

Debu Tripathy, MD, professor of medicine and co-leader of the Women’s Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, suggests the Oncotype DX recurrence score is useful in determining treatment options for patients with positive node breast cancer; since not all of these patients benefit from chemotherapy.

Tripathy describes that this idea is still controversial because the studies supporting it are not yet robust. A prospective study is currently underway examining 1-3 node breast cancer patients that are ER+ HER2 neu negative using the Oncotype DX recurrence score to randomize patients to receive either hormonal therapy or hormonal therapy in combination with chemotherapy.
Debu Tripathy, MD, professor of medicine and co-leader of the Women’s Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, suggests the Oncotype DX recurrence score is useful in determining treatment options for patients with positive node breast cancer; since not all of these patients benefit from chemotherapy.

Tripathy describes that this idea is still controversial because the studies supporting it are not yet robust. A prospective study is currently underway examining 1-3 node breast cancer patients that are ER+ HER2 neu negative using the Oncotype DX recurrence score to randomize patients to receive either hormonal therapy or hormonal therapy in combination with chemotherapy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x